Demant Financial Statements From 2010 to 2024

WILYY Stock  USD 19.37  0.51  2.70%   
Demant AS financial statements provide useful quarterly and yearly information to potential Demant AS ADR investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Demant AS financial statements helps investors assess Demant AS's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Demant AS's valuation are summarized below:
Demant AS ADR does not presently have any fundamental signals for analysis.
Check Demant AS financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Demant AS's main balance sheet or income statement drivers, such as , as well as many indicators such as . Demant financial statements analysis is a perfect complement when working with Demant AS Valuation or Volatility modules.
  
This module can also supplement various Demant AS Technical models . Check out the analysis of Demant AS Correlation against competitors.

Demant AS ADR Company Shares Outstanding Analysis

Demant AS's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current Demant AS Shares Outstanding

    
  446.37 M  
Most of Demant AS's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Demant AS ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

Based on the latest financial disclosure, Demant AS ADR has 446.37 M of shares currently outstending. This is 147.25% higher than that of the Healthcare sector and 155.15% higher than that of the Medical Devices industry. The shares outstanding for all United States stocks is 21.94% higher than that of the company.

Demant AS ADR Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Demant AS's current stock value. Our valuation model uses many indicators to compare Demant AS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Demant AS competition to find correlations between indicators driving Demant AS's intrinsic value. More Info.
Demant AS ADR is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about  0.26  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Demant AS ADR is roughly  3.88 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Demant AS by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Demant AS's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About Demant AS Financial Statements

Demant AS investors use historical fundamental indicators, such as Demant AS's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Demant AS. Please read more on our technical analysis and fundamental analysis pages.
Demant AS, a hearing healthcare and audio technology company, develops, manufactures, and sells products and equipment to enhance peoples hearing in Europe, North America, the Pacific, Asia, and internationally. Demant AS was founded in 1904 and is headquartered in Smrum, Denmark. Demant As is traded on OTC Exchange in the United States.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Demant Pink Sheet Analysis

When running Demant AS's price analysis, check to measure Demant AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Demant AS is operating at the current time. Most of Demant AS's value examination focuses on studying past and present price action to predict the probability of Demant AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Demant AS's price. Additionally, you may evaluate how the addition of Demant AS to your portfolios can decrease your overall portfolio volatility.